Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil Daud

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
Cancer Biology & Therapy|March 22, 2014
Melanoma immunotherapyMartina Sanlorenzo, Igor Vujic, Christian Posch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational studyPamela Münster, Douglas Marchion, Elona Bicaku, et al.
British Journal of Cancer|March 22, 2017
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapyAdi Nosrati, Katy K Tsai, Simone M Goldinger, et al.
Nature Communications|July 19, 2020
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancerManuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian, Steven Soignet, Don S Dizon, et al.
British Journal of Cancer|September 12, 2018
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006Omid Hamid, Caroline Robert, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant MelanomaAntoni Ribas, Adil Daud, Anna C Pavlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanomaDavid B Solit, Iman Osman, David Polsky, et al.
Immunotherapy|October 25, 2017
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)David A Canton, Shawna Shirley, Jocelyn Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid TumorsRandy F Sweis, Georgina V Long, Adil Daud, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
Cancer Biology & Therapy|March 22, 2014
Melanoma immunotherapyMartina Sanlorenzo, Igor Vujic, Christian Posch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational studyPamela Münster, Douglas Marchion, Elona Bicaku, et al.
British Journal of Cancer|March 22, 2017
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapyAdi Nosrati, Katy K Tsai, Simone M Goldinger, et al.
Nature Communications|July 19, 2020
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancerManuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian, Steven Soignet, Don S Dizon, et al.
British Journal of Cancer|September 12, 2018
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006Omid Hamid, Caroline Robert, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant MelanomaAntoni Ribas, Adil Daud, Anna C Pavlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanomaDavid B Solit, Iman Osman, David Polsky, et al.
Immunotherapy|October 25, 2017
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)David A Canton, Shawna Shirley, Jocelyn Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid TumorsRandy F Sweis, Georgina V Long, Adil Daud, et al.
Pageof 11